Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDerwent London Regulatory News (DLN)

Share Price Information for Derwent London (DLN)

Share Price is delayed by 15 minutes
Get Live Data
1,765.00    -13.00 (-0.73%)
Bid:
1,768.00
Ask:
1,771.00
Spread: 3.00 (0.17%)
Market Cap: £1.98b
DLN Live PriceLast checked at - London Stock Exchange

Intraday Derwent London Share Chart

Directorate change

22 Jan 2026 09:00

RNS Number : 9492P
Derwent London PLC
22 January 2026
Β 

Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Β 

Derwent London plc ("Derwent London" / "the Group")

PAUL WILLIAMS, CHIEF EXECUTIVE, TO RETIRE

Derwent London today announces that Paul Williams has informed the Board of his intention to retire as Chief Executive and Director of the Company.

Paul will remain in his role until his successor is in place at which point he will step down from the Board.

Paul's career at Derwent began shortly after the Company was founded in 1984. He was appointed as an Executive Director in 1998, with responsibility for leasing, asset management and development, and subsequently became Chief Executive in 2019.

A thorough process to appoint a successor, led by the Chairman Mark Breuer, will commence immediately.

Mark Breuer, Chairman, commented:Β 

"I would like to thank Paul for his dedication and commitment over the last 38 years. During his distinguished career, including his tenure as Chief Executive, he has made an outstanding contribution to Derwent London. With its market leading position, ongoing commitment to capital recycling and significant development pipeline, Derwent London is well placed to create significant value for shareholders."

Paul Williams, Chief Executive, said:

"It has been a huge privilege to have been part of the Derwent story and to have had the opportunity to lead the business over the last six years. I am very proud of what we have achieved, positioning the business with world class assets in prime locations across London, attracting sustained and strong occupational demand. I would like to thank my fellow directors and all the team for their continued hard work and support. I remain fully focused on driving the performance of the business until my successor is in place."

Information equivalent to that required under section 430(2B) of the UK Companies Act 2006 will be made available on the Company's website at the time Paul Williams steps down from the Board and in the Company's 2025 Directors' Remuneration Report.

For further information, please contact:

Derwent London

Tel: +44 (0)20 3478 4217 (Robert Duncan)

Mark Breuer, Chairman

David Lawler, Company Secretary

Robert Duncan, Head of Investor Relations

Brunswick Group

Tel: +44 (0)20 7404 5959

Β 

Β 

Simon Sporborg

Nina Coad

Notes to editors

Derwent London plc

Derwent London plc owns a commercial real estate portfolio predominantly in central London valued at Β£5.2 billion as at 30 June 2025, making it the largest London office-focused real estate investment trust (REIT).

Our experienced team has a long track record of creating value throughout the property cycle by regenerating our buildings via redevelopment or refurbishment, effective asset management and capital recycling. We typically acquire central London properties off-market with low capital values and modest rents in improving locations, most of which are either in the West End or City Borders. We capitalise on the unique qualities of each of our properties - taking a fresh approach to the regeneration of every building with a focus on anticipating tenant requirements and an emphasis on design. Reflecting and supporting our long-term success, the business has a strong balance sheet with modest leverage, a robust income stream and flexible financing.

We are frequently recognised in industry awards for the quality, design and innovation of our projects. Landmark buildings in our 5.3 million sq ft portfolio include 25 Baker Street W1, 1 Soho Place W1, 80 Charlotte Street W1, Brunel Building W2, White Collar Factory EC1, Angel Building EC1 and Tea Building E1.

As part of our commitment to lead the industry in mitigating climate change, Derwent London has committed to becoming a net zero carbon business by 2030, publishing its pathway to achieving this goal in 2020. Our science-based carbon targets have been validated by the Science Based Targets initiative (SBTi). In 2013, we launched a voluntary Community Fund which to date has supported 180 community projects in central London.

The Company is a public limited company, which is listed on the London Stock Exchange and incorporated and domiciled in the UK. The address of its registered office is 25 Savile Row, London, W1S 2ER.

For further information see www.derwentlondon.com or follow us on LinkedIn.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BOAGIGDBIBDDGLD
Date   Source Headline
2nd Jun 20262:00 pmRNSHolding(s) in Company
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:37 pmRNSTotal Voting Rights
26th May 20267:00 amRNSTransaction in Own Shares
21st May 20265:15 pmRNSDirector/PDMR Shareholding
19th May 202610:00 amRNSDirector Declaration
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202611:45 amRNSResult of AGM
12th May 20267:00 amRNSTrading Statement
1st May 202610:30 amRNSHolding(s) in Company
30th Apr 20264:45 pmRNSTotal Voting Rights
22nd Apr 20265:00 pmRNSHolding(s) in Company
22nd Apr 202610:15 amRNSHolding(s) in Company
20th Apr 202610:30 amRNSHolding(s) in Company
14th Apr 202611:14 amRNSAnnual Financial Report
10th Apr 20264:45 pmRNSAdmission to Trading
7th Apr 20265:12 pmRNSEmployee Benefit Trust (“EBT”)
7th Apr 20264:45 pmRNSDirector/PDMR Shareholding
2nd Apr 20267:00 amRNSAppointment of Barclays as joint corporate broker
1st Apr 20267:00 amRNSDisposal of Horseferry House SW1
31st Mar 20264:45 pmRNSTotal Voting Rights
27th Mar 202612:45 pmRNSDirector/PDMR Shareholding
24th Mar 202610:30 amRNSDirector/PDMR Shareholding
20th Mar 20264:15 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSNetwork building fully pre-let
16th Mar 20267:00 amRNSNetwork building fully pre-let
27th Feb 20264:45 pmRNSTotal Voting Rights
26th Feb 20267:32 amRNSDerwent London plc Disposal of 90 Whitfield Street
26th Feb 20267:00 amRNSResults for the Year Ended 31 December 2025
6th Feb 20264:40 pmRNSHolding(s) in Company
6th Feb 20267:00 amRNSDisposal of 80-85 Tottenham Court Road W1
30th Jan 20264:45 pmRNSTotal Voting Rights
22nd Jan 20269:00 amRNSDirectorate change
15th Jan 202611:00 amRNSHolding(s) in Company
31st Dec 20251:15 pmRNSTotal Voting Rights
31st Dec 20251:15 pmRNSTotal Voting Rights
17th Dec 20257:00 amRNSPlanning success at Blue Star House SW9
9th Dec 20257:00 amRNSBurberry extends commitment to Horseferry House
28th Nov 20254:45 pmRNSTotal Voting Rights
6th Nov 20257:00 amRNSThird Quarter Business Update
31st Oct 20254:45 pmRNSTotal Voting Rights
21st Oct 20257:00 amRNSStrategic partnership at Old Street Quarter
9th Oct 20257:00 amRNSSuccessful completion of 25 Baker Street
30th Sep 20254:45 pmRNSTotal Voting Rights
30th Sep 202511:00 amRNSHolding(s) in Company
22nd Sep 202512:00 pmRNSBlock listing Interim Review
9th Sep 202511:45 amRNSDirector Declaration
2nd Sep 202511:30 amRNSHolding(s) in Company
29th Aug 20254:45 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.